The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xydalba



AbbVie Deutschland GmbH & Co. KGEU/1/14/986/001

Main Information

Trade NameXydalba
Active SubstancesDalbavancin hcl
Dosage FormPowder for concentrate for solution for infusion
Licence HolderAbbVie Deutschland GmbH & Co. KG
Licence NumberEU/1/14/986/001

Group Information

ATC CodeJ01XA Glycopeptide antibacterials
J01XA04 dalbavancin

Status

License statusAuthorised
Licence Issued19/02/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back